Genomics Vugene We specialize in cutting edge genomic analysis, helping researchers and industry professionals make data driven decisions. our expertise spans: we handle sequencing data preprocessing and analysis based on best practices and gold standards. Vugene, founded in 2021, is a lithuania based multi omics data analysis and interpretation company. being a service as a software company, vugene enables characterization of treatment models and improved understanding of disease mechanisms.
Genomics Vugene Vugene was founded in 2021 to offer analysis and interpretation services for genomic, transcriptomic, epigenomic, proteomic, single cell, and other types of biological data. Vugene, a lithuanian company specializing in multi omics data analysis, has announced the successful closing of a €1 million funding round. the investment was led by superhero capital, with participation from ngl ventures, coinvest capital, and several angel investors, according to the announcement made on vugene’s website. I had an opportunity to present vugene’s innovative approach towards biomedical data analysis and had an honor to attend 19th national conference on health economy #gesundheit2024 in rostock. By helping scientists better understand complex biological data in health and disease research, this lithuanian startup is already working with leading research centres and biotech companies.
Epigenomics Vugene I had an opportunity to present vugene’s innovative approach towards biomedical data analysis and had an honor to attend 19th national conference on health economy #gesundheit2024 in rostock. By helping scientists better understand complex biological data in health and disease research, this lithuanian startup is already working with leading research centres and biotech companies. Founded in 2021 by juozas gordevičius, vugene has developed a platform able to integrate biological data from all sources – transcriptomics, (epi)genomics, metabolomics, proteomics involving spatial and single cell methods. Lithuanian company vugene, which focuses on multi omics data analysis, has raised €1 million in a funding round. the investment was led by superhero capital, with support from ngl ventures, coinvest capital, and several angel investors, according to a statement on vugene’s website. We specialize in omics data analysis, including genomics, epigenomics, transcriptomics, metabolomics, proteomics, single cell approaches, and multi omics integration. Under the deal, inotiv will apply vugene’s platform — which analyzes genomics, transcriptomics, proteomics, metabolomics and epigenomics — to identify biomarkers and prioritize targets.
Comments are closed.